Encinitas, California--(Newsfile Corp. - September 25, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in the following investor conferences. The presentations will be accessible live and on-demand for 90 days from our IR homepage (ir.kiorapharma.com).
Monday, October 1, 2024 at 10:15 am EDT
Presenter: Melissa Tosca, Chief Financial Officer
Click here to register and view
To arrange a meeting with management, please email 1×This email address is being protected from spambots. You need JavaScript enabled to view it.
Tuesday, October 15, 2024 at 11:00 am EDT
Presenter: Brian M. Strem, Ph.D., Chief Executive Officer
Click here to sign up (account creation required), register and view
Tuesday, October 29 at 4:00 pm EDT
Presenter: Melissa Tosca, Chief Financial Officer
Click here to register and view
About Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
In addition to news releases and SEC filings, we expect to post information on our website (www.kiorapharma.com) and social media accounts that could be relevant to investors. We encourage investors to follow us on Twitter and LinkedIn as well as to visit our website and/or subscribe to email alerts.
Contacts:
Investors
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.94 |
| Daily Change: | -0.06 -1.90 |
| Daily Volume: | 734 |
| Market Cap: | US$8.830M |
April 04, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
